Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, on lipid metabolism in an open randomized trial

Contraception

Volumn 54, Issue 5, 1996, Pages 291-297

  Brill, Klaus ^a   Then, A ^b   Beisiegel, U ^c   Jene, A ^c   Wunsch C ^a   Leidenberger, F ^b  

^a BAYER PHARMA AG   (Germany)

^b Weise and Partner   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

combined oral contraceptive; ethinylestradiol; gestodene; HDL cholesterol; LDL cholesterol; lipid metabolism; triglycerides

Indexed keywords

APOLIPOPROTEIN; ETHINYLESTRADIOL; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; LYMPHADENOPATHY; NORMAL HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

EID: 0030297689     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00182-5     Document Type: Article

References (12)

1. 1. Scheafer EJ, Foster DM, Zech LA, et al. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262-7.
2. 2. Lipson A, Stoy DB, LaRosa JC, et al. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study. Contraception 1986;34:121-34.
3. 3. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862-7.
4. 4. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives found in the Framingham Study. Ann Intern Med 1979; 90:85-91.
5. 5. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterowich PO. Association of coronary atherosclerosis with hyperapobetalipoproteinemia. Proc Natl Acad Sci USA 1980;77:604-8.
6. 6. Miller NE, Forde OH, Thelle DS, et al. The Tromsøq-heart study. High-density lipoprotein and coronary heart disease: a prospective case control study. Lancet 1977;i:965-7.
7. 7. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707-14.
8. 8. Ishikawa T, Fidge N, Thelle DS, et al. The Tromsø heart study: serum apolipoprotein AI concentration in relation to future coronary heart disease. Eur J Clin Invest 1978;8:179-82.
9. 9. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-8;672-7.
10. 10. Bottiger LE, Boman G, Eklund G, Westerholme B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;i:1097-101.
11. 11. Meade TW, Grunberg G, Thompson SC. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 ug oestrogen preparations. Br Med J 1980;1:1157-61.
12. 12. Redgrave DD, Raberts DCK, West CE. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem 1975;65:42-9.